RWO with chemotherapy for patients who progress after PACIFIC regimen
Stephen Liu shared a post on X about a recent paper by Hayato Kawachi et al. published in Clinical Lung Cancer.
Authors: Hayato Kawachi, Motohiro Tamiya, Yuko Oya, Koichi Takayama, Kazumi Nishino et al.
“Real world outcomes with chemotherapy for patients who progress after PACIFIC regimen (durvalumab after chemoradiation for stage III NSCLC) Clinical Lung Cancer.
Platinum based chemotherapy had PFS 13.2m if durvalumab PFS ≥1y but only 4.7m if durva PFS < 1y…”
Source: Stephen Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.
Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.